Mostafa Yazdimamaghani

University of North Carolina at Chapel Hill — United States

Engineering · Physical Sciences

26h-index2.6kcitations60works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone Tissue Engineering Materials(15), Nanoplatforms for cancer theranostics(11), MicroRNA in disease regulation(8), Nanoparticle-Based Drug Delivery(8), Nanoparticles: synthesis and applications(8)

Publications60 total

Liver-targeted delivery of bioengineered induced tregs via nanoparticles prevents and treats acute gvhd
Blood·2025Open Access
High-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancer
UNC Libraries·2025Open Access
Tumor-specific surface marker–independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry
Journal of Clinical Investigation·2025· 2 citedOpen Access
Engineering PAMAM dendrimers for optimized drug delivery
Nano Trends·2025· 16 citedOpen Access
Type II innate lymphoid cell plasticity contributes to impaired reconstitution after allogeneic hematopoietic stem cell transplantation
UNC Libraries·2024Open Access
Optimized Fabrication of Dendritic Mesoporous Silica Nanoparticles as Efficient Delivery System for Cancer Immunotherapy
Small·2024· 12 citedOpen Access
Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy
UNC Libraries·2024Open Access
Corrigendum to “Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy” [Biomaterials 312 (2025) 122750
UNC Libraries·2024Open Access
Corrigendum to “Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy” [Biomaterials 312 (2025) 122750
Biomaterials·2024Open Access
Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy
Biomaterials·2024· 18 citedOpen Access
Type II innate lymphoid cell plasticity contributes to impaired reconstitution after allogeneic hematopoietic stem cell transplantation
Nature Communications·2024· 9 citedOpen Access
Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis
UNC Libraries·2024Open Access
Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy
2024· 3 citedOpen Access
High-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancer
Nano Today·2023· 38 citedOpen Access
Abstract 1810: Enhanced anti-breast tumor cancer activity using nano-formulated TLR 7/8 agonist and PI3K inhibitor
Cancer Research·2023
Supplementary Data from Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis
2023Open Access
Data from Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis
2023Open Access
Data from Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis
2023Open Access
Supplementary Data from Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis
2023Open Access
High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer
2022· 4 cited
page 1 of 3Next →

Frequent Co-authors

Lobat Tayebi(20), Daryoosh Vashaee(14), Mehdi Razavi(11), Hamidreza Ghandehari(11), Jonathan S. Serody(7), Chaemin Lim(6), Duhyeong Hwang(6), Alexander V. Kabanov(6), Daryoosh Vashaee(5), Andrew Z. Wang(5), Charles M. Perou(5), Oleg Kolupaev(5), Seyyed Pouya Hadipour Moghaddam(4), Raziye Mohammadpour(4), Hossein Sendi(4), Nikhila Sultanpuram(4), Amber S. Moody(4), Amanda L. Graboski(4), Juan D. Rojas(4), Paul A. Dayton(4)